Top Markets
Coin of the day
Chordia Therapeutics Inc. Chordia Therapeutics Inc.

Chordia Therapeutics Inc.

190A
Clasificación en acciones #26484
Chordia Therapeutics Inc., a biotech company, engages in research and... Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Precio por acción
$0.53499835
Capitalización bursátil
$40.24M
Cambio (1 día)
2.50%
Cambio (1 año)
-58.07%
País
JP
Comercio Chordia Therapeutics Inc. (190A)

Categoría

Ganancias de Chordia Therapeutics Inc. (190A)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Chordia Therapeutics Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Chordia Therapeutics Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$-3.09B -
US